SEARCH

SEARCH BY CITATION

References

  • 1
    NCIPC. Traumatic brain injury—factsheet: National Center for Injury Prevention and Control, Center for Disease Control and Prevention ; 2006. http://www.cdc.gov/ncipc/tbi/TBI.htm (accessed 23 January 2007).
  • 2
    Reilly PL, Graham DI, Adams JH, Jennett B. Patients with head injury who talk and die. Lancet 1975;2:375377.
  • 3
    Unterberg A, Baethmann A, Lanksch W. Prevention and treatment of secondary brain damage. Clinical aspects. Chest 1991;100(Suppl. 3):200S202S.
  • 4
    Vincent JL, Berre J. Primer on medical management of severe brain injury. Crit Care Med 2005;33:13921399.
  • 5
    Francel PC. Bradykinin and neuronal injury. J Neurotrauma 1992;9(Suppl. 1):S27S45.
  • 6
    Mayhan WG. Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension. Brain Res 1996;738:337341.
  • 7
    Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004;129:10211029.
  • 8
    Marmarou A, Nichols J, Burgess J, Newell D, Troha J, Burnham D, Pitts L. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group . J Neurotrauma 1999;16:431444.
  • 9
    Ker K, Blackhall K. Beta-2 receptor antagonists for acute traumatic brain injury. Cochrane Database Syst Rev 2008;CD006686.
  • 10
    Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I. Where is the evidence that animal research benefits humans? Br Med J 2004;328:514517.
  • 11
    Sandercock P, Roberts I. Systematic reviews of animal experiments. Lancet 2002;360:586.
  • 12
    Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. 2005. http://www.cochrane-handbook.org (accessed 30 April 2007).
  • 13
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629634.
  • 14
    Hellal F, Pruneau D, Palmier B, Faye P, Croci N, Plotkine M, Marchand-Verrecchia C. Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J Neurotrauma 2003;20:841851.
  • 15
    Ivashkova Y, Svetnitsky A, Mayzler O, Pruneau D, Benifla M, Fuxman Y, Cohen A, Artru AA, Shapira Y. Bradykinin B2 receptor antagonism with LF 18–1505T reduces brain edema and improves neurological outcome after closed head trauma in rats. J Trauma 2006;61:879885.
  • 16
    Kaplanski J, Pruneau D, Asa I, Artru AA, Azez A, Ivashkova Y, Rudich Z, Shapira Y. LF 16–0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma 2002;19:953964.
  • 17
    Plotkine M. Effects of LF 16–0687 Ms in a mouse model of head trauma. Study report: Laboratories Fournier; 2001. Report No.: MP/CHTS/1999–1.
  • 18
    Plotkine M. Effect of LF 16–0687 Ms and CP 0127 in a mouse model of head trauma. Study report: Laboratoires Fournier; 2001 December 2001. Report No.: MP/CHTS/2000–2.
  • 19
    Pruneau D, Chorny I, Benkovitz V, Artru A, Roitblat L, Shapira Y. Effect of LF 16–0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J Neurotrauma 1999;16:10571065.
  • 20
    Shapira Y. Effect of subcutaneous administration of LF 16–0687 Ms a new Bradykinin B2 receptor antagonist in a rat model of closed head trauma. Study report: Laboratoires Fournier; 2001 November 2001. Report No.: YS/CHTR 1999–3.
  • 21
    Shapira Y. The therapeutic window of subcutaneous LF 16–0687 Ms a new Bradykinin B2 receptor antagonist, following closed head trauma in rats. Project VIII: Laboratoires Fournier; 2001 April 2001.
  • 22
    Shapira Y. Effect of 1, 2 or 3 days subcutaneous administration of LF 16–0687 Ms a new Bradykinin B2 receptor antagonist on closed head trauma in a rat model. Project IX: Laboratoires Fournier; 2002 January 2002. Report No.: YS/CHTR 2000–4.
  • 23
    Stover JF, Dohse NK, Unterberg AW. Bradykinin 2 receptor antagonist LF 16–0687Ms reduces posttraumatic brain edema. Acta Neurochir Suppl 2000;76:171175.
  • 24
    Stover JF, Dohse NK, Unterberg AW. Significant reduction in brain swelling by administration of nonpeptide kinin B2 receptor antagonist LF 16–0687Ms after controlled cortical impact injury in rats. J Neurosurg 2000;92:853859.
  • 25
    Stover JF, Dohse NK, Unterberg AW. Effect of LF 16–0687 Ms on edema formation following controlled cortical impact injury in the rat: Laboratoires Fournier; 2001.
  • 26
    Stover JF, Unterberg AW. Dose-dependent effects of LF 16–0687 Ms on brain edema formation and CSF glutamate concentrations following controlled cortical impact injury in the rat: Laboratoires Fournier; 2001 May 2001. Report No.: JS/CCII 2000–2.
  • 27
    Stover JF, W SO, Dohse NK, Stroop R, Unterberg AW. Effects of LF 16–0687 Ms on brain edema, contusion, cortical perfusion, EEG activity, extracellular and CSF glutamate and intracranial pressure following controlled cortical impact injury in the rat: Laboratoires Fournier; 2001 May, 2001. Report No.: JS/CCII 2000–1.
  • 28
    Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007;334:197.
  • 29
    Macleod M, O’Collins T, Howells D, Donnan G. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004;35:12031208.